Mortality from cirrhosis: lack of progress over the last 35 years

Gluud, C.
November 2005
Gut;Nov2005, Vol. 54 Issue 11, p1523
Academic Journal
Liver cirrhosis mortality does not seem to have changed significantly during the last 30 years in the Oxford region! How come? There are risks of erroneous findings (patient mix consequences, wrong sampling unit, diagnostic misclassification, type II errors), lack of beneficial effects of interventions considered to be effective, and incorrect implementation of interventions.


Related Articles

  • Treatment of Hepatitis B in Decompensated Liver Cirrhosis. Guan, Richard; Lui, Hock Foong // International Journal of Hepatology;2011, p1 

    Chronic hepatitis B infection progresses from an asymptomatic persistently infected state to chronic hepatitis, cirrhosis, decompensated liver disease, and/or hepatocellular carcinoma. About 3% of patients with chronic hepatitis develop cirrhosis yearly, and about 5% of individuals with...

  • Management of HBV- and HCVinduced end stage liver disease. Mutimer, David J.; Lok, Anna // Gut;May2012 Supplement 1, Vol. 61, pi59 

    Hepatitis B and hepatitis C infections are important causes of end-stage liver disease and primary liver cancer. Successful antiviral treatment prior to the development of cirrhosis will prevent most of the morbidity and mortality associated with those infections. This can be achieved for a high...

  • Antiviral Therapy in Chronic Hepatitis C Virus-related Decompensated Liver Cirrhosis -- A Tightrope Walk. Amarapurkar, Deepak N. // Saudi Journal of Gastroenterology;Oct2010, Vol. 16 Issue 4, p245 

    The author considers the association of antivirals for treatment of chronic hepatitis C virus (HCV) with liver cirrhosis. He offers figures about HCV-related end-stage liver disease and HCV-related decompensated cirrhosis. He mentions some key points of the American Association of Study of Liver...

  • Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis. Ooga, Hiromi; Suzuki, Fumitaka; Tsubota, Akihito; Arase, Yasuji; Suzuki, Yoshiyuki; Akuta, Norio; Sezaki, Hitomi; Hosaka, Tetsuya; Someya, Takashi; Kobayashi, Masahiro; Saitoh, Satoshi; Ikeda, Kenji; Kobayashi, Mariko; Matsuda, Marie; Satoh, Junko; Kumada, Hiromitsu // Journal of Gastroenterology;2004, Vol. 39 Issue 11, p1078 

    Background. Several clinical trials have suggested that lamivudine therapy is effective in patients with hepatitis B virus (HBV)-related cirrhosis. However, there are few studies of lamivudine therapy in Japanese patients with HBV cirrhosis. The aim of this study was to evaluate the efficacy of...

  • Hepatitis C Virus Genotype 3: Hope for Nonresponders and Patients With Cirrhosis.  // Experimental & Clinical Hepatology;Jun2014, Vol. 4 Issue 2, p179 

    Background: In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates among patients with hepatitis C virus (HCV) genotype 2 infection, with lower response rates among patients with...

  • Living-Donor Liver Transplantation and Hepatitis C. Nobuhisa Akamatsu; Yasuhiko Sugawara // HPB Surgery;2013, p1 

    Hepatitis-C-virus- (HCV-) related end-stage cirrhosis is the primary indication for liver transplantation in many countries. Unfortunately, however, HCV is not eliminated by transplantation and graft reinfection is universal, resulting in fibrosis, cirrhosis, and finally graft decompression. In...

  • Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level. Chen, Chien-Jen; Yang, Hwai-I.; Su, Jun; Jen, Chin-Lan; You, v; Lu, Sheng-Nan; Huang, Guan-Tarn; Iloeje, Uchenna H. // JAMA: Journal of the American Medical Association;1/4/2006, Vol. 295 Issue 1, p65 

    t: Serum hepatitis B virus (HBV) DNA level is a marker of viral replication and efficacy of antiviral treatment in individuals with chronic hepatitis B. Objective: To evaluate the relationship between serum HBV DNA level and risk of hepatocellular carcinoma. Design, Setting, and Participants:...

  • Serum level of YKL-40 does not predict advanced liver fibrosis in children with chronic hepatitis B. Lebensztejn, D. M.; Skiba, E.; Werpachowska, I.; Sobaniec-Łotowska, M. E.; Kaczmarski, M. // Advances in Medical Sciences (De Gruyter Open);2007, Vol. 52, p120 

    Purpose: The aim of the study was to evaluate the serum concentration of YKL-40 (human cartilage glycoprotein-39) in the assessment of fibrosis stage in children compared to biopsy and prior to antiviral treatment for chronic hepatitis B. Material and methods: We determined serum level of YKL-40...

  • The Impact of Antiviral Therapy and the Influence of Metabolic Cofactors on the Outcome of Chronic HCV Infection. Persico, Marcello; Bruno, Savino; Costantino, Andrea; Mazza, Marta; Almasio, Piero Luigi // International Journal of Hepatology;2011, p1 

    Natural history of HCV related chronic hepatitis is influenced and modified by many factors: virus features, coinfections and host characteristics. In particular, a peculiar genetic background of the host by conditioning the occurrence of intracellular metabolic derangements (i.e., insulin...


Read the Article


Sign out of this library

Other Topics